



(51) International Patent Classification:

A61K 9/20 (2006.01) A61K 31/4422 (2006.01)
A61K 9/28 (2006.01) A61K 9/00 (2006.01)
A61J 3/00 (2006.01) A61K 9/24 (2006.01)
A61K 31/4184 (2006.01)

(21) International Application Number:

PCT/EP2013/059110

(22) International Filing Date:

2 May 2013 (02.05.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12167035.0 7 May 2012 (07.05.2012) EP
13151946.4 18 January 2013 (18.01.2013) EP

(71) Applicant: **BAYER PHARMA AKTIENGESELLSCHAFT** [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(72) Inventors: **FUNKE, Adrian**; Insterburgallee 33a, 14055 Berlin (DE). **MEYER, Günter**; Nachodstr. 21, 10779 Berlin (DE). **SMIKALLA, Martina**; Weiherstr. 6, 40219 Düsseldorf (DE). **MEENERS, Andreas**; Fasanenstr. 24, 41334 Nettetal (DE). **WIRGES, Markus**; Am Botanischen Garten 10, 40225 Düsseldorf (DE). **BROCK, Daniela**; Kaldenberger Weg 24, 40822 Mettmann (DE). **JUST, Sarah**; Starenweg 48, 50259 Pulheim (DE). **KLEINEBUDDE, Peter**; Vennstraße 124, 40627 Düsseldorf (DE). **KNOP, Klaus**; Färberstr. 27a, 40764 Langenfeld (DE). **ZEITLER, Jochen, Axel**; Gonville and Caius College, Trinity Street, Cambridge, Cambridgeshire CB2 1TA (GB). **BOEGGERING, Rolf-Anton**; Paracelsusstr. 16, 41564 Kaarst (DE).

(74) Agent: **BIP PATENTS**; c/o Bayer Intellectual Property GmbH, Creative Campus Monheim, Alfred-Nobel-Str. 10, 40789 Monheim (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: PROCESS FOR MANUFACTURING A PHARMACEUTICAL DOSAGE FORM COMPRISING NIFEDIPINE AND CANDESARTAN CILEXETIL

(57) Abstract: The present invention relates to manufacturing processes for the preparation of a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil and optionally at least one diuretic characterized in that nifedipine is released in the body in a controlled (modified) manner and the candesartan cilexetil is released rapidly (immediate release (IR)) and optionally the diuretic is released rapidly (immediate release (IR)) and the pharmaceutical dosage forms obtainable by these processes.

